Preparation and optimization of chitosan nanoparticles as carrier of anti-Alzheimer tacrine drug and size estimation of nanoparticles by chemometrics

Mohammadreza Khanmohammadi; Hamideh Elmizadeh; Gholamreza Hassanzadeh; Marjan Nassiri-Asl

Journal of Inflammatory Diseases

The Official Journal of Qazvin University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Editors & Boards Indexing and Listing Sources Reviewer and AE Registration Form Journal Metrics Open Peer Review (OPR)Publication Ethics and Publication Malpractice Statement Support Contact Us

Authors Guide Submit Manuscript

Preparation and optimization of chitosan nanoparticles as carrier of anti-Alzheimer tacrine drug and size estimation of nanoparticles by chemometrics

Author(s):

Mohammadreza Khanmohammadi¹,

Hamideh Elmizadeh^,*,

Gholamreza Hassanzadeh²,

Marjan Nassiri-Asl³

1Department of Chemistry, Faculty of Science, Imam Khomeini International University, Qazvin, Iran

2Department of Anatomy, Tehran University of Medical Science, Tehran, Iran

3Department of Pharmacology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

Journal of Inflammatory Diseases:Vol. 17, issue 5; 10-16

Article type:Research Article

How to Cite:Mohammadreza KhanmohammadiHamideh ElmizadehGholamreza HassanzadehMarjan Nassiri-AslPreparation and optimization of chitosan nanoparticles as carrier of anti-Alzheimer tacrine drug and size estimation of nanoparticles by chemometrics.J Inflamm Dis.17(5):e155777.

Abstract

Abstract Background: Several drug delivery systems were developed during the 1980s and 1990s to improve the efficiency of drugs and minimize toxic side effects. Nanoparticles have the ability to deliver a wide range of drugs to varying areas of the body for sustained periods of time. Objective: The aim of study was to preparation and optimization of chitosan nanoparticles carrier systems of Anti-Alzheimer tacrine drug and estimation of particle size by Chemometrics. Methods: This was an experimental study conducted at Chemistry school of Imam Khomeini International University (Qazvin, Iran) in 2011-2012. Chitosan nanoparticles were prepared by spontaneous emulsification method. In order to optimize the method of chitosan nanoparticles preparation, Design of Experiment (DOE) was employed using Box–Behnken response surface methodology. Also, chitosan nanoparticles containing tacrine were prepared using the optimal synthesis method provided by the experimental design. Forty two different chitosan nanoparticles samples with different particle size were analyzed by DRIFT spectrometry and the obtained data were processed by PLS. Nano-sized particles and their morphological state were determined by field emission scanning electron microscopy (FE-SEM). Findings: In accordance with Box–Behnken experimental design, optimum amount of NaCl as an electrolyte (0.52 %), Span 80 as a surfactant (10 %) and Glutaraldehyde Saturated Toluene )GST( as a chemical cross-linking agent (4.86 mL) were used for the synthesis method. The designed nanoparticles have average particle size from 33.64 to 74.87 nm. Yield percentage and drug loading percentage of chitosan nanoparticles that were synthesized according to the optimum method were 90 % and 13.4 ± 0.51 %, respectively. The estimated sizes of chitosan nanoparticles give promise to a robust and reliable calibration that confirms correlation coefficient )R2 (and Root Mean Square Error (RMSE) of 0.98 and 3.59. Conclusion: Based on findings of the present study, Preparation of chitosan nanoparticles as delivery systems for the anti-Alzheimer drug tacrine with minimum particle size and spherical morphology was the goals of this study. Also, the findings suggest that the analysis of nano particle samples by DRIFT and data processing by PLS-NAS would provide a novel method for average nano particle size estimation. PLS-NAS model established is characterized by high linearity, precision and speed of analysis.

Keywords

Nanoparticles

Tacrine

Drug Delivery Systems

Alzheimer Disease

comments